PTGS2 and myocardial infarction: The recent withdrawal of rofecoxib together with new data showing that other cyclo-oxygenase-2 (COX-2) inhibitors might also be associated with an increased risk of developing adverse cardiovascular events, mainly acute myocardial infarction (MI), has created a climate of uncertainty surrounding the safety of these drugs and traditional non-steroidal anti-inflammatory drugs (tNSAIDs) [1,2].